Neutralizing antibodies (inhibitors) towards factor VIII form a severe complication in nonsevere hemophilia A, profoundly aggravating the bleeding pattern. Identification of high risk patients is hampered by lack of data that take exposure days to therapeutic factor VIII concentrates into account. In the INSIGHT study we analyzed the association between F8 mutation and inhibitor development in patients with nonsevere hemophilia A (factor VIII, 2-40 IU dL -1
INTRODUCTION
Patients with hemophilia A who are treated with factor VIII concentrates are at risk of developing factor VIII neutralizing alloantibodies (inhibitors).
l;2 Inhibitor development is one of the most challenging complications in the treatment of hemophilia A as it increases the bleeding tendency, while it renders the treatment with therapeutic factor VIII concentrates ineffective. Treatment of patients with inhibitors can be very complicated and costly. 3 Although inhibitor development is less frequently observed in patients with nonsevere hemophilia A (baseline factor VIII activity of 2-40 IU dL -1 ), the clinical impact can be profound. In these patients, inhibitors may also interact with their endogenous factor VIII, resulting in a decrease of the factor VIII plasma level below 1 IU dL -1 and major bleeding complications. 4 Identification of patients at risk of developing inhibitors may help to prevent this serious complication. However, there are currently no tools available to predict individual inhibitor risk in nonsevere hemophilia patients.
The type of mutation in the factor VIII gene (F8) is an important risk factor for inhibitor development. [5] [6] [7] Nonsevere hemophilia A is generally caused by F8 missense mutations. 8 Despite information on large numbers of F8 mutations associated with nonsevere hemophilia A that is collected in international databases, 9;10 it is not possible to calculate the inhibitor risk for specific F8 mutations as data on exposure days to therapeutic factor VIII concentrates are lacking. Moreover, there may be a reporting bias in these databases favouring registration of those with identified inhibitors.
As inhibitor development is elicited by the exposure to therapeutic factor VIII, the risk of developing inhibitors strongly depends on the cumulative number of exposure days. Information about exposure to factor VIII concentrates is especially important in nonsevere hemophilia A patients as they receive factor VIII replacement therapy on an irregular basis and much less frequently than severe hemophilia A patients on account of having milder bleeding phenotypes. Previous studies in severe hemophilia A demonstrate the risk of developing inhibitors after more than 50 exposure days decreases to less than 1%. 1 The majority of patients with severe hemophilia A receives fifty exposure days within the first few years of life. However, in nonsevere hemophilia A, even some adult patients may still have less than 50 exposure days to therapeutic factor VIII and thus still be at risk of developing inhibitors.
This study includes the largest cohort of patients with nonsevere hemophilia A to assess the risk of inhibitor development. It is the first analysis of the association between inhibitor development and F8 mutation in nonsevere hemophilia that takes cumulative exposure to therapeutic factor VIII concentrates into account. This provides valuable data enabling a more personalised inhibitor risk estimation which is of immediate clinical relevance. Moreover, it may improve our understanding of alloreactivity in response to an intravenous protein therapeutic.
PATIENTS AND METHODS

Subjects and study design
This retrospective cohort study includes patients from a source population consisting of all patients (n = 2,711) with nonsevere hemophilia A (baseline factor VIII activity of 2-40 IU dL -1 ), who received at least one exposure to factor VIII concentrate between January 1 st 1980 (when factor VIII concentrates became more widely available) and January 1 st 2011 in one of the 34 participating hemophilia treatment centers of the INSIGHT study. Participating centers (listed in the appendix) were located in ten European countries and Australia. The institutional review boards of all participating centers approved the study and have indicated that signed informed consent was not required. All patients from the source population were followed-up from birth until death, emigration, loss-to-follow-up or the end of the study.
Because inhibitor patients may be more likely to be genotyped we were concerned that inhibitor patients would be overrepresented in our cohort. To reduce the risk of selection bias we restricted our analysis to all patients (n = 1,112) of the centers that had genotyped at least 70% of their patients (see flowchart of patients, Figure 1 ). The cut-off of ≥70% was arbitrarily chosen before initial analysis. In these 14 centers -located in eight countriespatients were genotyped as part of routine practice independent of patient characteristics. Patients were included in the center where they received treatment with factor VIII concentrates (prior to inhibitor development). Patients who were referred to a participating center once they had already developed an inhibitor were excluded from the analysis.
Data collection
Data were collected from medical records using a standardized electronic case report form. The following data on patient characteristics were collected: date of birth, ethnicity, F8 mutation, family history of hemophilia and inhibitors. Additionally, we collected data on the total number of days on which the patient was exposed to therapeutic factor VIII concentrates before inhibitor development or the end of the follow-up period. An exposure day was defined as a calendar day during which one or more infusions of factor VIII concentrates were administered. Cumulative number of exposure days were classified into the following seven categories: 1-5, 5-10, 10-20, 20-30, 30-50, 50-100 and >100 exposure days. Detailed information for each exposure day -such as date, factor VIII product type and reason for treatment -were not necessary for the analysis of the association between inhibitor development and F8 mutation and were not collected due to feasibility reasons.
Laboratory tests and F8 mutation analysis
Results of the following laboratory tests were collected to confirm the diagnosis of nonsevere hemophilia A: baseline factor VIII activity (FVIII:C, assessed by the one-stage clotting factor VIII assay, 2-40 IU dL -1 ), von Willebrand factor antigen level (VWF:Ag) and von Willebrand factor activity (VWF:RCo). Patients with FVIII:C levels < 2 IU dL -1 were not included in the study to avoid misclassification and inclusion of severe hemophilia A patients as older FVIII:C tests were less precise in measuring the lower ranges of FVIII:C. F8 mutation was collected from authorized genetic laboratory reports in the patient' s records or derived from his pedigree (in 5.3% of the patients) when the causative mutation had been identified in another family member. Standard methods for the analysis of the F8 were used at each individual laboratory as described previously.
11 Each mutation was reviewed and identified using the traditional nomenclature, based on the mature processed protein. Amino acid numbering for point mutations is given for the mature processed protein, as used universally in F8 studies. To convert to Human Genome Variation Society (HGVS)-type numbering add 19 to positive numbers.
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Definition of inhibitor development
Inhibitor tests were done at the discretion of each center and the results of all inhibitor tests were reviewed to confirm the inhibitor status of the patients (no data on the number Figure 1 . Flowchart of patients included in the study of inhibitor tests performed on each patient were available). Inhibitory antibodies were quantified at each local laboratory by the original Bethesda method or the Nijmegen modified assay from the nineties onwards.
13;14
Only patients with a clinically relevant inhibitor were classified to be positive for an inhibitor in the analysis. A clinically relevant inhibitor was defined as having at least two positive Bethesda inhibitor assay titers of ≥ 1.0 Bethesda Inhibitor Assay Unit per mL (BU mL -1 ). A high titer inhibitor was defined as a historical peak titer > 5.0 BU mL -1 . Patients with inhibitor titers between 0.6-1.0 BU mL -1 had to fulfill one of the following two criteria to be classified as having a clinically relevant inhibitor: 1.) a decrease in factor VIII plasma level to at least 50% of the baseline level, or 2.) a reduced half-life after factor VIII administration of less than six hours. Patients who were not tested for factor VIII inhibitors during the follow-up period and who had no clinical features of inhibitor development (e.g. increased bleeding tendency) were classified as negative for inhibitors (n = 5).
Data analysis
To adjust for the varying number of cumulative exposure days to factor VIII concentrates we calculated Kaplan-Meier cumulative inhibitor incidences with inhibitor development as the event and the cumulative number of exposure days as the time variable. Missing values of cumulative exposure days were imputed using multiple linear regression methods in 4% of the patients. 15 For F8 mutations carried by > 10 subjects, Kaplan-Meier cumulative inhibitor incidences were interpreted as inhibitor risk and are presented as percentages with 95% confidence interval (CI). To enable comparison of inhibitor risk between F8 mutations at a certain time point in treatment, cumulative inhibitor incidences are given at 20 and 50 exposure days. The risk is calculated by dividing the number of inhibitor patients with a specific mutation by the total number of patients with the same mutation that have a certain number of exposure days (e.g. 20 or 50 exposure days). Thus, an inhibitor risk of 30% after 50 exposure days for a specific mutation means that after 50 exposure days to therapeutic factor VIII concentrates 30% of the patients with this mutation developed an inhibitor.
RESULTS
Patient characteristics
In total 1,112 subjects with a confirmed diagnosis of nonsevere hemophilia A received one or more exposures to factor VIII concentrate and were included in the study population. Patients were born between 1908 and 2009, and were observed for approximately 25,700 patient years and 44,800 exposure days with a median follow-up of 38 years (Inter Quartile Range (IQR), 18-56) and 24 exposure days (IQR, 7-90) per patient. Two-thirds of patients had fewer than 50 exposure days at the end of follow-up (n = 755; 68%), most of them (n = 517) had fewer than 20 exposure days. These and other demographic characteristics of the patients were comparable to that of the source population of 2,711 patients, and are listed in Table 1 . . At inhibitor detection, 30 patients (51%) had an increased bleeding tendency and 47 patients (80%) needed treatment for bleeding when the inhibitor was present. In 11 inhibitor patients (19%) there was no clinical sign of inhibitor development at presentation and the inhibitor was detected during routine inhibitor testing. The inhibitor became undetectable in 42 out of 59 patients (71%) after a median of 45 weeks (IQR, 13-108): in 12 patients (29%) after inhibitor eradication therapy (immune tolerance induction n = 7, immunosuppressive therapy n = 4, both n = 1), in 30 patients (71%) the inhibitor cleared spontaneously without specific inhibitor eradication therapy (of whom 18 where rechallenged to factor VIII concentrates after the inhibitor became undetectable) and in three patients (5%) eradication therapy was unknown. In 14 patients (15%) the inhibitor was still present at the end of follow-up and in three patients (5%) inhibitor status at the end of follow-up was unknown ( Figure 1 ).
Inhibitor development
Inhibitors were detected after a median of 28 exposure days (IQR, 12-71). Fortyone patients (69%) developed an inhibitor before their 50 th exposure day, 17 patients (29%) between 50 and 100 exposure days, and only one patient (2%) after more than 100 exposure days. The inhibitor risk at 20 and 50 exposure days was 3.5% (95% CI, 2.1-4. 9) and 6.7% (CI, 4.5-8. 9) respectively. The inhibitor risk was 13.3% (CI, 9.6-17.0) in patients with 100 exposure days ( Figure 2) .
Patients who developed inhibitors were comparable to patients who did not develop inhibitors regarding ethnicity (inhibitor patients 97% Caucasian; non-inhibitor patients 95% Caucasian) and severity of disease (inhibitor patients: median FVIII:C, 10 IU dL ; IQR, 6-18).
F8 mutations
F8 genotype was known in 895 patients (81%) of the study population (n = 1,112) and in 51 (51/59; 86%) patients who had developed an inhibitor. In total, 214 different missense mutations (n = 865 patients; 78%) and 17 other mutations (n = 30 patients; 3%) were identified in F8 (supplemental Table 1 ). The most prevalent amino acid substitutions were Arg593Cys (9%), Arg2150His (5%), Asn618Ser (5%) and Arg531Cys (3%). The complete list of mutations of the centers that had genotyped at least 70% of their patients (n = 1,112) and of the total INSIGHT cohort (n = 2,711) are presented in supplemental Table 1 and 2. There was a wide variation of baseline FVIII:C levels within patients carrying the same F8 mutation (supplemental Table 1 and 2) which could not be explained by interlaboratory variability or variation of FVIII:C assays over time. There was a variation in inhibitor risk between FVIII:C levels, however, there was no trend observed towards patients with lower FVIII:C levels having the highest inhibitor risk (data not shown).
Association between inhibitors and F8 mutation
Nineteen mutations (Leu412Phe, Arg531Cys, Arg593Cys, Asn618Ser, Pro1761Gln, Phe1775Val, Arg1781Gly, Pro1854Leu, Arg1997Trp, Asp2074Gly, Phe2101Cys, Tyr2105Cys, Arg2150His, Arg2159Cys, Glu2228Asp, Trp2229Cys, Val2232Ala, His2309Asp, Stop2333Cys) were associated with inhibitor development and were all located in the A2 domain of the heavy chain and in the A3, C1 and C2 domains of the light chain of the factor VIII protein (Figure 3 ). These mutations were all missense mutations in F8 and were identified in a total of 
(15.3)
No. indicates number; and ED, exposure days. *% of total cohort of patients (n=1,112). † End of follow-up for each F8 mutation is defined as the maximum number of exposure days to factor VIII concentrates observed during follow-up for at least one patient with this F8 mutation. ‡ The risk is calculated by dividing the number of inhibitor patients with a specific mutation by the total number of patients with the same mutation that have a certain number of exposure days (e.g. 20 or 50 exposure days). § Inhibitor risk is 0 at 50ED because the patient with this mutation that developed an inhibitor did so after 95 exposure days. **One of the patients with the Arg593Cys mutation who developed an inhibitor also had a polymorphism in the promoter of the F8 gene (c.-112G>A).
DISCUSSION
This is the largest cohort of nonsevere hemophilia A patients in which the inhibitor risk and its association with F8 mutations has been assessed, taking exposure days into account.
The inhibitor risk was 6.7% at 50 exposure days, rising to 13.3% at 100 exposure days. We identified 19 mutations associated with inhibitor development -of which seven were not reported with inhibitors previously -from a total of 214 different missense mutations. 9 ;10 This information emphasizes the importance of F8 genotyping in nonsevere hemophilia A patients. It also demonstrates the importance of reporting inhibitor occurrence to either of the international databases, if these are to be an important ongoing resource for inhibitor risk assessment. 16 Importantly, the risk of inhibitor development in patients with nonsevere hemophilia approaches the risk of severe hemophilia patients when inhibitor development is evaluated as a function of exposure to factor VIII concentrates. 1;17 This highlights the substantial risk of inhibitor development in nonsevere hemophilia A patients that has previously been underestimated. Given that unexposed patients were excluded from the study population and that a large proportion of patients (68%) included in the study had fewer than 50 exposure days, there is a large population of unchallenged patients that might need treatment with factor VIII concentrates in the future. Thus, inhibitor development in nonsevere hemophilia A patients may become an important future burden of care in hemophilia treatment.
As the inhibitor risk of several missense mutations approaches that of severe patients, this may suggest that these single amino acid mutations are highly immunogenic. Previous observations suggest that both position and type of substitution of missense mutations may influence the inhibitor risk. Consistent with these observations the mutations associated with inhibitors in the INSIGHT cohort were all located within the regions encoding for the light chain and the A2 domain of factor VIII. 8 A recent study by Schwaab and colleagues indicates that the risk of inhibitor formation is significantly higher if the substituted amino acid in the factor VIII protein belongs to another physicochemical class than the original residue. 18 Our study was epidemiological in nature and did not aim to elucidate the immunological mechanism underlying the association of the F8 gene mutation and inhibitor risk. This will definitely be an important aim for future studies in this field. There was a wide variation in inhibitor risk between patients with different FVIII:C levels and no trend was observed, therefore the relation between F8 mutation and inhibitor risk could not be explained by FVIII:C level.
An unexpected high incidence of inhibitors occurred after 50 exposure days. Development of inhibitors later in life has recently been recognised in hemophilia A patients with prior extensive exposure to factor concentrates. 17;19 The possibility of age related immune dysregulation and late loss of tolerance may be particularly relevant to the nonsevere hemophilia cohort, as exposure to therapeutic factor VIII concentrates is distributed throughout life and often skewed to later decades for elective operative interventions. Current hypotheses suggest that this may be elicited by the clinical circumstances during exposure that trigger the immune system, such as intensive treatment with factor VIII concentrates for surgery.
20;21 Although we adjusted for cumulative number of exposure days, the present analysis does not take potential clinical risk factors -such as factor VIII product type and intensity and reason for treatment -into account. [19] [20] [21] However, it is highly unlikely that these clinical risk factors have influenced the observed association between F8 genotype an inhibitor development due to the principle of Mendelian randomization: inheritance of a certain genotype is "random" and will not be influenced by environmental determinants of inhibitor development. 22 When interpreting the results of this study there are certain limitations that should be kept in mind. We obtained data from nonsevere patients that did receive treatment with factor VIII concentrates. Patients with a very mild bleeding phenotype or those exclusively treated with desmopressin were not included. As those who need treatment with factor VIII concentrates do not represent all nonsevere hemophilia A patients, the incidence of inhibitors in the total nonsevere hemophilia A population will be lower than reported in our study. The applicability of our results is also limited to Caucasian populations, as the study population was mainly Caucasian.
Because family members who share the same F8 mutation are more likely to share allelic variants of other genes, e.g. immune-response genes (TNFA, IL-10 or CTLA-4) that increase the risk for inhibitor development in severe hemophilia A, we cannot exclude that other inherited factors may also have contributed to the observed associations. [23] [24] [25] [26] There is one situation that may lead to a biased estimate of the effect of F8 genotype on inhibitor risk. This is illustrated in the article by Sheehan and colleagues. 27 If there is another gene that on the one hand affects inhibitor risk, and on the other hand is linked to the F8 mutation, this other gene may confound the association between F8 mutation and disease. Currently there are no data on a gene linked to F8 which also causes inhibitors, but it is of course theoretically possible. The low incidence (2.3%) of patients with a positive family history of inhibitors in our cohort is likely to be a function of challenges of data collection associating a particular individual with other family members (especially when they are treated in different centers) and emphasises the need for decent family tree maintenance.
Despite the large number of patients included in our study, we acknowledge that our study has limited statistical power to calculate the inhibitor risk for most of the F8 mutations, because these mutations only occur in a small number of patients or because the patients with these specific mutations have a limited number of exposure days. However, considering the extent of this study it may never be duplicated or studied prospectively. Given that inhibitors were not regularly tested in all patients following a predefined regimen, we may have missed patients with asymptomatic or transient inhibitors, especially in the beginning of the observation period . Therefore the inhibitor incidences in our study may be underestimated. To reduce the potential influence of interassay and interlaboratory variability on inhibitor classification we used clinically relevant inhibitor as the outcome measure.
28
Our study identifies a higher incidence of inhibitor development in nonsevere hemophilia than previously appreciated and has made the first step towards identification of high risk patients based on their F8 genotype. As there are currently no proven strategies to prevent inhibitor development in nonsevere hemophilia patients, further research to develop preventive strategies is urgently needed. In the absence of these strategies, we propose that desmopressin response should be tested in all nonsevere hemophilia A patients to optimize the use of desmopressin in adequate responders as an effective and safe alternative for factor VIII concentrates, without the risk of inhibitor development.
29 This is relevant since it appears that at least some high risk mutations respond well to desmopressin administration.
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Our study also highlights the potential of F8 genotyping to estimate individualized risks of inhibitor formation for those mutations with sufficient data. It can inform the patient-doctor consultation, contributing to the decision whether to proceed with an elective intervention and how to manage it, and may therefore be of immediate clinical relevance. Moreover, the results of our study contribute to our knowledge of alloreactivity in response to an intravenous protein therapeutic. 
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Abbreviations are explained in Table 2 .
* Because inhibitor patients may be more likely to be genotyped we were concerned that inhibitor patients would be overrepresented in our cohort. To reduce the risk of selection bias we restricted our analysis to all patients (n = 1,112) of the centers that had genotyped at least 70% of their patients. In these 14 centers patients were genotyped as part of routine practice independent of patient characteristics. † % of total cohort of patients (n=1,112). ‡ End of follow-up for each F8 mutation is defined as the maximum number of exposure days to factor VIII concentrates observed during follow-up for at least one patient with this F8 mutation.
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* Contrary to Supplemental Table 1, Supplemental table 2 is not restricted to the centers that had genotyped at least 70% of their patients as part of routine practice.
Please note that inhibitor patients may be overrepresented in this table as inhibitor patients may be more likely to be genotyped. † % of total cohort of patients (n=2,711). ‡ End of follow-up for each F8 mutation is defined as the maximum number of exposure days to factor VIII concentrates observed during follow-up for at least one patient with this F8 mutation.
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